ES2880813T3 - Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas - Google Patents

Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas Download PDF

Info

Publication number
ES2880813T3
ES2880813T3 ES11734283T ES11734283T ES2880813T3 ES 2880813 T3 ES2880813 T3 ES 2880813T3 ES 11734283 T ES11734283 T ES 11734283T ES 11734283 T ES11734283 T ES 11734283T ES 2880813 T3 ES2880813 T3 ES 2880813T3
Authority
ES
Spain
Prior art keywords
naproxen
weight
amount
formulation
ranges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11734283T
Other languages
English (en)
Spanish (es)
Inventor
John Lopez
Peter Draper
Sankalp Vashishtha
Nancy Klassen
Christina Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Ontario Ltd
Original Assignee
Catalent Ontario Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Ontario Ltd filed Critical Catalent Ontario Ltd
Application granted granted Critical
Publication of ES2880813T3 publication Critical patent/ES2880813T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11734283T 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas Active ES2880813T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Publications (1)

Publication Number Publication Date
ES2880813T3 true ES2880813T3 (es) 2021-11-25

Family

ID=44303618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11734283T Active ES2880813T3 (es) 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas

Country Status (13)

Country Link
US (5) US9480667B2 (cg-RX-API-DMAC10.html)
EP (2) EP3909567B1 (cg-RX-API-DMAC10.html)
JP (2) JP5975884B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011207061B2 (cg-RX-API-DMAC10.html)
CA (1) CA2690488C (cg-RX-API-DMAC10.html)
DK (1) DK2525789T3 (cg-RX-API-DMAC10.html)
ES (1) ES2880813T3 (cg-RX-API-DMAC10.html)
HU (1) HUE055771T2 (cg-RX-API-DMAC10.html)
MX (1) MX358636B (cg-RX-API-DMAC10.html)
PL (1) PL2525789T3 (cg-RX-API-DMAC10.html)
PT (1) PT2525789T (cg-RX-API-DMAC10.html)
SI (1) SI2525789T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011088553A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业(武汉)有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
CR20200552A (es) 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
AU2020263295B2 (en) * 2019-04-26 2025-01-23 R.P. Scherer Technologies, Llc Mini softgel naproxen composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
AU706890B2 (en) * 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US7582679B2 (en) 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Also Published As

Publication number Publication date
US12605348B2 (en) 2026-04-21
JP5975884B2 (ja) 2016-08-23
US20260216111A1 (en) 2026-07-30
CA2690488A1 (en) 2011-07-19
WO2011088553A1 (en) 2011-07-28
JP2016094462A (ja) 2016-05-26
AU2011207061A1 (en) 2012-07-26
PL2525789T3 (pl) 2022-01-03
EP2525789A1 (en) 2012-11-28
MX2012008300A (es) 2012-11-23
US10463637B2 (en) 2019-11-05
DK2525789T3 (da) 2021-07-19
EP3909567C0 (en) 2026-04-29
JP2013517304A (ja) 2013-05-16
SI2525789T1 (sl) 2021-12-31
EP3909567B1 (en) 2026-04-29
CA2690488C (en) 2013-06-11
EP3909567A1 (en) 2021-11-17
EP2525789A4 (en) 2014-04-30
US11896566B2 (en) 2024-02-13
MX358636B (es) 2018-08-29
US20240139132A1 (en) 2024-05-02
AU2011207061B2 (en) 2015-05-28
EP2525789B1 (en) 2021-06-02
US9480667B2 (en) 2016-11-01
US20170020832A1 (en) 2017-01-26
PT2525789T (pt) 2021-07-19
US20130011470A1 (en) 2013-01-10
US20200046662A1 (en) 2020-02-13
HUE055771T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
US12605348B2 (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
ES2603225T3 (es) Sistema de cápsulas blandas sin gelatina
ES2792082T3 (es) Estabilidad mejorada de composiciones líquidas novedosas
ES2556217T3 (es) Formulación en bolsa para polímeros de amina
US20030232097A1 (en) Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
ES2641889T3 (es) Formulaciones de diclofenaco y métodos de uso
ES2424492T3 (es) Composición pulverulenta o granulada que comprende un copolímero, una sal de un ácido monocarboxílico graso y un ácido monocarboxílico graso y/o un alcohol graso
JP2009197015A (ja) ハードシェルカプセル剤のためのイブプロフェン溶液
WO2008070950A1 (en) Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
WO2005046727A2 (en) Ibuprofen-containing soft gelatin capsules
JP4394447B2 (ja) アセトアミノフェン組成物
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
ES2488191T3 (es) Composición farmacéutica que contiene un extracto de Serenoa repens
CA3207235A1 (en) Concentrated liquid gel formulations containing naproxen salts
ES2316308A1 (es) Medicamente a base de metronidazol y acido azelaico para el tratamiento por via topica de la enfermedad rosacea de mejor asimilacion, y procedimiento de preparacion.